Real-world efficacy and safety of selpercatinib in <i>RET</i> -mutant medullary thyroid cancer at a Tertiary Referral Center
In real-word settings, selpercatinib showed high efficacy and tolerability, particularly as first-line treatment. Our findings support its use as the preferred initial targeted treatment for RET-driven MTC beyond clinical trial populations.
Authors
- Yara Maria Machlah (ORCID: https://orcid.org/0009-0001-9441-3046)
- Tim Brandenburg
- F. Weber (ORCID: https://orcid.org/0000-0002-5739-5643)
- Lahner Harald
- Dagmar Führer
- Sarah Theurer
- Lynn Marlene Srasra
Institutions
- European Neuroendocrine Tumor Society (DE)
- West Cancer Center (US)
- Essen University Hospital (DE)
- University of Duisburg-Essen (DE)
Publication Details
- Journal
- European Journal of Endocrinology
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1093/ejendo/lvaf256
- Citations
- 1
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.29